Refractory or Relapsed B Cell Lymphoma
Conditions
Keywords
Allogeneic CAR T，B cell Lymphoma
Brief summary
This is a phase 1/2, open-label study to assess the efficacy, safety and pharmacokinetics of ThisCART19A (Allogeneic Anti CD19 CAR-T) in patients with refractory or relapsed CD19 positive B cell Lymphoma.
Detailed description
This is a phase 1/2, single-center, nonrandomized, open-label, dose-escalation and dose-expansion study to evaluate the efficacy, safety and pharmacokinetics of ThisCART19A in patients with r/r CD19 positive B cell Lymphoma and identify a treatment regimen most likely to result in clinical efficacy while maintaining a favorable safety profile. AIDS-related B-cell lymphoma were not excluded from this clinical trial. Before initiating ThisCART19A infusion, subjects will be administered lymphodepletion chemotherapy composed of fludarabine、cyclophosphamide and VP-16. At Day 0 of the Treatment Period, subjects will receive an intravenous (IV) infusion of ThisCART19A. All subjects are monitored during the treatment period through Day 42. All subjects who receive a dose of ThisCART19A will be followed up to 2 years.
Interventions
DRUGThisCART19A
Single dose of Allogeneic Anti-CD19 CAR T cells (ThisCART19A) will be infused after the lymphodepletion conditioning of Fludarabine, Cyclophosphamide and Etoposide.
DRUGFludarabine
Fludarabine is used for lymphodepletion.
DRUGCyclophosphamide
Cyclophosphamide is used for lymphodepletion.
DRUGEtoposide
Etoposide is used for lymphodepletion.
Sponsors
Fundamenta Therapeutics, Ltd.
Chongqing University Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. 18 years ≤ age ≤ 65 years. 2. Voluntarily sign a documented IRB-approved ICF prior to any screening procedure. 3. Patients with histologically confirmed B-cell NHL defined by the World Health Organization (WHO) 2016, including but not limited to diffuse large B-cell lymphoma (DLBCL), follicular lymphoma transferring to DLBCL, mantle cell lymphoma (MCL), follicular lymphoma 3B (FL-3B), original Mediastinal (thymus) large B-cell lymphoma, high-grade B-cell lymphoma and AIDS-associated B-cell lymphoma. 4. Prior therapy must have included: Anti-CD20 monoclonal antibody and Anthracycline containing chemotherapy regimen. 5. Had available evaluation lesion. 6. ECOG(Eastern Cooperative Oncology Group) ≤ 2 or Karnofsky ≥ 60%. 7. Serum creatinine≤1.5×ULN or creatinine clearance\>30 mL/min/1.73 m2. 8. Alanine aminotransferase(ALT)≤5×ULN(Upper limit of normal) and total bilirubin(TBIL)\<2.0 mg/dL(for patients with Gilbert heald diseases, live involvement and taking atazanavir or indinavir, TBIL\<3.0 mg/dL can be enrolled.) 9. Left ventricular ejection fraction(LVEF)≥40% 10. Absolute neutrophile counts≥1000/mm3 11. Thrombocyte≥30000/mm3 12. Total bilirubin(TBIL) ≤ 2.0 mg/dL 13. Confirmed Cluster of differentiation(CD)19 positive by biopsy for the patients who received CD19 target therapy before. 14. Pregnancy tests for women of childbearing age shall be negative; Both men and women agreed to use effective contraception during treatment and during the subsequent 1 year. 15. AIDS Related B Cell Lymphoma :HIV virus loading \< 200 copy/ml and CD4+T cell counts \>200 cells/mm3 within 4 weeks before screening. 16. Patients with TBIL≤ 1.5 mg/dL, Aspartate aminotransferase(AST) and ALT ≤ 3×ULN, and hepatitis B virus(HBV) DNA \<2000 IU/ml can be enrolled for HBV positive patients(defined as hepatitis B virus surface antigen(HBsAg) positive and hepatitis B core(HBc)-total positive ) and hepatitis C virus(HCV) positive patients(defined as HCV antibody positive) . Patients with cirrhosis are excluded. 17. Hepatitis B core antibody(HBcAb) positive patients enrolled in this trial have to taking anti-HBV drugs during the whole research.
Exclusion criteria
1. Known for allergic to the preconditioning measures. 2. Uncontrollable bacterial, fungal, viral infection before enrollment. 3. Patients with pulmonary embolism within 3 months prior enrollment. 4. Intolerable serious cardiovascular and cerebrovascular diseases and hereditary diseases. 5. Imaging confirmed the presence of central nervous system involvement(including primary and secondary) and rapid progressing diseases. 6. Receive allogeneic hematopoietic stem cell transplantation less than 100 days. 7. Systemic steroid use (e.g., prednisone ≥20mg) within 3 days prior to screening. iIntermittent use of topical, inhaled or intranasal steroids recently or currently. Or systemic disease requiring long-term use of immunosuppression drugs. 8. Excluded the patients received Influenza vaccinations within 2 weeks prior to lymphodepletion (Received Severe Acute Respiratory Syndrome-Corona virus disease(SARS-COV)19 vaccines could be included. Received inactivated, live/non-live adjuvant vaccines could be enrolled). 9. Excluded women who are in pregnant or lactating, and female subjects or partners who plan to be pregnant within 1 year after infusion. Male subjects planning pregnancy within 1 year after infusion should be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of all grade TEAEs and ≥3 grade TEAEs | Up to 2 years after ThisCART19A infusion | Incidence of treatment-emergent adverse events (TEAEs) and ≥3 grade TEAEs |
| Duration of response (DOR) | Up to 2 years after ThisCART19A infusion | DOR is defined as the date of their first CR or PR (which is subsequently confirmed) to PD assessed by investigators and based on the Lugano 2014 assessment criterion for r/r B cell Lymphoma, or death regardless of cause. |
| Progress-free survival (PFS) | Up to 2 years after ThisCART19A infusion | PFS is defined as the time from the ThisCART19A infusion date to the date of disease progression assessed by investigators and based on the Lugano 2014 assessment criterion, or death any cause. |
| Dose limited toxicity(DLT) observation in patient with r/r B cell Lymphoma | 28 days | DLT was defined as CAR T cells-related events with onset within first 28 days following infusion. |
| Objective Response Rate | Up to 2 years after ThisCART19A infusion | the incidence of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or unevaluable (UE) as best response to treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS (Overall survival) | Up to 2 years after lymphodepletion | Overall survival (OS) is defined as the time from the date of lymphodepletion until death from any cause. |
| TTR (Time to response) | Up to 2 years after ThisCART19A infusion | TTR is defined as the time from ThisCART19A infusion to first assessed CR or PR based on the Lugano 2014 assessment criterion. |
Countries
China
Contacts
Primary ContactYao Liu, MD
Backup ContactJun Li, Ph.D
Outcome results
None listed